Drug Profile
Research programme: antibody therapeutics - Eloxx Pharmaceuticals
Alternative Names: FB 001; FB 002; FB 003 - Eloxx Pharmaceuticals; FB 004; G protein-coupled receptor modulators - Eloxx Pharmaceuticals; Ion channel antagonists - Eloxx Pharmaceuticals; SVN-001; SVN-002Latest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator Fabrus
- Developer Eloxx Pharmaceuticals
- Class Antibodies
- Mechanism of Action Angiogenesis modulating agents; G protein-coupled receptor modulators; Immunomodulators; Ion channel antagonists; Kv1.3 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Inflammation; Pain
Most Recent Events
- 29 Mar 2023 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral)
- 29 Mar 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 29 Mar 2023 Discontinued - Preclinical for Inflammation in USA (Parenteral)